PubRank

Juan Carlos Lacal

Author PubWeight™ 44.29‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 2007 2.35
2 Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002 2.09
3 Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 2005 1.97
4 Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004 1.53
5 Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta 2004 1.45
6 Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007 1.44
7 Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One 2009 1.23
8 Rho GTPases: potential candidates for anticancer therapy. Cancer Lett 2004 1.23
9 Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol 2008 1.19
10 Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002 1.19
11 Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. Mol Biol Cell 2002 1.18
12 Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004 1.16
13 Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003 1.13
14 Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells. Mol Cancer 2009 1.13
15 Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 2005 1.12
16 ROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences. Mol Biol Cell 2003 1.08
17 TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann Surg Oncol 2008 1.06
18 Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Int J Biochem Cell Biol 2008 1.04
19 Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets 2008 1.03
20 Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions. Adv Enzyme Regul 2010 1.02
21 Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncol 2005 1.00
22 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol 2005 0.97
23 Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer. Int J Biochem Cell Biol 2007 0.95
24 Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clin Transl Oncol 2011 0.94
25 A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells. Am J Pathol 2007 0.93
26 From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett 2004 0.92
27 Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One 2013 0.90
28 Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target. Int J Radiat Oncol Biol Phys 2012 0.88
29 STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA. Mol Biol Cell 2003 0.87
30 Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Prog Cell Cycle Res 2003 0.84
31 Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer. Int J Oncol 2006 0.82
32 Influence of the linker in bispyridium compounds on the inhibition of human choline kinase. J Med Chem 2004 0.82
33 New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties. J Med Chem 2004 0.80
34 Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium. Cancer Biol Ther 2012 0.80
35 Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1. Int J Oncol 2002 0.79
36 Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds. Bioorg Med Chem 2002 0.79
37 Human urine proteomics: building a list of human urine cancer biomarkers. Expert Rev Proteomics 2011 0.79
38 Antiplasmodial activity and mechanism of action of RSM-932A, a promising synergistic inhibitor of Plasmodium falciparum choline kinase. Antimicrob Agents Chemother 2013 0.78
39 Lights and shadows of proteomic technologies for the study of protein species including isoforms, splicing variants and protein post-translational modifications. Proteomics 2011 0.78
40 A novel 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazol with antitumoral activity via cell cycle arrest and induction of apoptosis. Int J Oncol 2004 0.76
41 Protein chimerism: novel source of protein diversity in humans adds complexity to bottom-up proteomics. Proteomics 2012 0.76
42 Anticancer research: a few hints for discovery of new targets. Cancer Lett 2004 0.75
43 Bad patients meet good drugs. Clin Transl Oncol 2006 0.75
44 Clinical and Translational Oncology accepted in SciSearch and journal citation reports. Clin Transl Oncol 2008 0.75